explore -WSS

explore

author：knowledge 2025-09-29 21:14:40 - browse：49274

Anna Yeo/STAT

Recently approved gene therapies offer patients one-time, potentially curative treatments for genetic diseases such as sickle cell anemia and beta thalassemia. But “one-time” miracle solutions can often be multi-month affairs, require millions of dollars, and cause painful side effects. What if that doesn’t have to be the case?

In utero gene editing, or prenatal somatic cell genome editing, envisions treating a fetus diagnosed with a genetic disease before birth, thereby preventing that entire protocol and the onset of symptoms in the first place. It would also challenge the need for the ethically fraught enterprise of embryo editing, as the treatment would only make edits in the DNA of the individual fetus — edits which would not be passed on in a heritable way.

Watch this video to learn more about in utero gene editing, how it works, and why scientists believe it might be an advantageous approach to treating certain genetic diseases.

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： New weight loss drugs work. But how can they best be used?

WSS

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

A single drug, study failures leave Anavex with nothing but cash

U.K. sequencing study surfaces new findings about tumor DNA

Antibiotic resistance and the global rise in human conflict

Ahead of JPM, here's who's profiting most in health care

Why psychiatrists like me stop taking insurance

hotspot

explore

entertainment

Activists slam private health insurers over coverage restrictions

3 medical device trends to watch in 2024

Malaria cases in Florida and Texas: Here’s what you need to know

UCB departs biotech trade group BIO

At least 13 dead in Texas as scorching temps continue

JPM: CVS says Medicare Advantage patients are impacting profits

Virginia high school admissions case could be legal follow

Burning questions for the 2024 JPM Healthcare Conference

Apple is now the first public company to be valued at $3 trillion

Feng Zhang, Grail founder join forces on new gene editing startup

knowledge

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

3 trends to watch in health tech's hiring outlook for 2024

The FDA must approve intranasal treatments for anaphylaxis

The FDA must approve intranasal treatments for anaphylaxis

White House finalizes ITC's import ban of latest Apple Watches

entertainment

hotspot

hotspot

entertainment